Nurix Therapeutics, Inc. NRIX NX-1607 — R&D

Similar metrics at other companies

ZYMEExpense for other preclinical and research programs — R&D

$7.26M+19.6%

BCRXResearch, discovery and preclinical programs — Research and Development Expense (Excluding Acquired in Process Cost)

$3.97M+30.4%

DYNDYNE-251DM1 — Research And Development Expense

$37.75M+79.0%

ARQTOther program costs — R&D

$95K-92.0%

AXSMR&D

$52.68M+17.6%

BCRXBCX17725 — Research and Development Expense (Excluding Acquired in Process Cost)

$1.91M-22.4%

Questions, answered.

What is Nurix Therapeutics, Inc.'s NX-1607 — R&D?

Nurix Therapeutics, Inc. (NRIX) reported NX-1607 — R&D of $1.19M in Q4 2025.

How has Nurix Therapeutics, Inc.'s NX-1607 — R&D changed year-over-year?

Nurix Therapeutics, Inc.'s NX-1607 — R&D decreased by 39.4% year-over-year, from $1.96M to $1.19M.

What does NX-1607 — R&D mean?

This metric represents the direct operating expenses allocated to the research and development of a specific clinical-stage therapeutic candidate. It captures the investment in preclinical studies, clinical trials, and manufacturing process development required to advance this specific asset toward regulatory approval. Monitoring this spend provides insight into the company's capital allocation strategy and the prioritization of its pipeline assets.